Suppr超能文献

甲型 H1N1 流感疫苗。

Vaccines against influenza A (H1N1) pandemic.

机构信息

Laboratorios de Biológicos y Reactivos de México (BIRMEX), México D.F., México.

出版信息

Arch Med Res. 2009 Nov;40(8):693-704. doi: 10.1016/j.arcmed.2009.10.008.

Abstract

BACKGROUND AND AIMS

The World Health Organization (WHO) has reported, as of September 2009, that the influenza A (H1N1) influenza pandemic has originated >300,000 laboratory-confirmed cases and 3917 deaths in 191 countries. It is recognized that pandemic vaccines have their greatest impact as a preventive strategy when administered before or near the peak incidence of cases in an outbreak. Therefore, vaccination campaigns should be in place when influenza A (H1N1) 2009 vaccines are available. We undertook this study to provide updated information on clinical evaluation of influenza A (H1N1) vaccines and review recommendations for influenza A (H1N1) vaccination campaigns and public health policy.

METHODS

The following methods were used: 1) review of registry at ClinicalTrials.gov. 2) search of PubMed Central (PMC) for influenza A (H1N1) vaccine. 3) review of recommendations of WHO, Mexican Health Secretariat (SSA) and Advisory Committee on Immunization Practices (ACIP) on influenza A (H1N1) vaccination campaigns.

RESULTS

Until October 1, 2009 there were 11 available influenza A (H1N1) candidate strains provided by WHO Global Influenza Surveillance Network. ClinicalTrials.gov registers 45 phase I and II clinical trials evaluating immunogenicity and safety of influenza A (H1N1) vaccines. Preliminary results support administration of a single dose and use of adjuvants. Main recommendations of WHO, SSA and ACIP include epidemiologic considerations, objectives, definition of target groups and reinforcement of other mitigation measures.

CONCLUSIONS

The present pandemic of influenza A (H1N1) has shown mild to moderate severity. Vaccination strategies in Mexico will have the objective of decreasing severe outcomes, slowing transmission, protecting groups at increased risk of infection, complications, or death, and preventing overload of health services. Control of the pandemic should include reinforcement of other non-pharmacologic measures of mitigation and, importantly, an adequate strategy of social communication.

摘要

背景与目的

截至 2009 年 9 月,世界卫生组织(WHO)报告称,甲型 H1N1 流感大流行已在 191 个国家造成超过 30 万例实验室确诊病例和 3917 例死亡。人们认识到,大流行疫苗作为一种预防策略,在疫情爆发时或接近病例高峰时进行接种,效果最佳。因此,在有甲型 H1N1 2009 疫苗时,应开展疫苗接种运动。我们开展这项研究,是为了提供有关甲型 H1N1 疫苗临床评估的最新信息,并审查甲型 H1N1 疫苗接种运动和公共卫生政策的建议。

方法

采用以下方法:1)在 ClinicalTrials.gov 上查阅注册资料。2)在 PubMed Central(PMC)上搜索甲型 H1N1 疫苗。3)审查世界卫生组织、墨西哥卫生部(SSA)和免疫实践咨询委员会(ACIP)关于甲型 H1N1 疫苗接种运动的建议。

结果

截至 2009 年 10 月 1 日,世界卫生组织全球流感监测网络提供了 11 种可用的甲型 H1N1 候选株。ClinicalTrials.gov 注册了 45 项 I 期和 II 期临床试验,评估了甲型 H1N1 疫苗的免疫原性和安全性。初步结果支持接种单剂疫苗和使用佐剂。世界卫生组织、SSA 和 ACIP 的主要建议包括流行病学考虑因素、目标、目标人群定义以及加强其他缓解措施。

结论

目前的甲型 H1N1 流感大流行表现为轻度至中度严重程度。墨西哥的疫苗接种策略将以减少严重后果、减缓传播、保护感染、并发症或死亡风险增加的人群以及防止卫生服务超负荷为目标。大流行的控制应包括加强其他非药物缓解措施,重要的是,要有一个适当的社会沟通策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验